Does the PCSK9 rs11591147 GG genotype lack the LDL-lowering and cardioprotective effect of the R46L variant?

The PCSK9 rs11591147 polymorphism is a major genetic determinant of low-density lipoprotein receptor (LDLR) density and circulating lipid clearance.

Molecular mechanisms of clearance

• The R46L (T allele) variant acts as a loss-of-function mutation, exhibiting a twofold weaker affinity for LDLR and slower intracellular trafficking, which reduces mature, functional PCSK9 levels. This preserves hepatocyte surface LDLRs, preventing their degradation and facilitating accelerated clearance of circulating LDL-C.
• In contrast, the wild-type GG genotype maintains baseline, fully functional PCSK9 activity. Because the GG genotype does not disrupt the LDLR degradation pathway, these individuals experience normal rates of receptor clearance and lack this specific genetic mechanism for enhanced LDL-C clearance.

Clinical and cardiovascular evidence

• Carriers of the R46L mutation benefit from a lifetime LDL-C reduction of approximately 0.5 mmol/L (roughly 19 mg/dL), translating to a 17% to 23% lower risk of coronary heart disease. The mutation is also associated with a significantly reduced risk of aortic valve stenosis.
• Non-carriers with the homozygous GG genotype do not inherit these lifetime lipid-lowering and cardioprotective benefits, representing the standard population baseline for cardiovascular risk.

Metabolic trade-offs

• While the lifetime LDL-C lowering of the R46L variant provides robust cardiovascular protection, genetic data indicate it is also associated with a modest but significantly increased risk of type 2 diabetes mellitus, a pattern consistent with other intensive LDL-lowering mechanisms.

Bottom line

• The wild-type rs11591147 GG genotype preserves normal PCSK9 function and lacks the R46L-mediated loss-of-function effect, meaning individuals with this genotype do not receive the lifetime LDL-C clearance advantage and protective cardiovascular benefits associated with the T allele.